Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Completed

Conditions studied: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

In brief

* The primary aim of this study is to evaluate the impact of titration, analgesics, and 12 month telephone follow-up period from the B.E.T.A nurse program upon adherence to treatment with Betaseron in patients with a first clinical demyelinating event suggestive of Multiple Sclerosis (MS) and patients with onset of RRMS within the past 12 months * Secondary outcomes include analysis of the following parameters: progression of clinical severity by the expanded disability status scale (EDSS score), health related quality of life (HrQoL), and safety. * Exploratory outcomes include changes over time in cytokine and neurotrophic factor production by immune cells and visual function as assessed by visual examination, OCT measurements and a neuro-ophthalmologic Health-Related Quality of Life questionnaire (NEI-VFQ-25) with 10-item supplement.

Key facts

Study ID

NCT00461396

Run by

Bayer

People needed

104

Starts

2007-05-01

Expected to finish

2009-11-01

Last updated by the study team

2011-04-08

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have no cognitive impairment that may prevent patient from completing questionnaires, as assessed by examining physicians during screening
• Diagnosis of early (<1 year since onset) RRMS, or a first clinical episode suggestive of demyelinating disease (not explained by other conditions) within the last 90 days prior to screening
• Presence of at least 2 typical MS lesions by brain MRI
• Kurtzke Expanded Disability Status Scale (EDSS) score of 0 - 4.0
• Willing to enroll into the MS Pathways support program and by doing so agree to be trained, and have follow-up phone calls, by a B.E.T.A. nurse

You may not qualify if…

• Any disease other than multiple sclerosis that would better explain the patient's neurological signs and symptoms
• Complete transverse myelitis or simultaneous onset of optic neuritis
• Diagnosis of Primary progressive MS, secondary Progressive MS, relapsing progressive MS or a diagnosis of relapsing remitting MS for greater than 12 months
• Clinically significant heart disease such as uncontrolled cardiac dysrhythmias, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled heart failure
• History of severe, uncontrolled, or untreated depression, attempted suicide or suicidal ideation
• Uncontrolled seizure disorder
• History or hypergammaglobulinemia
• Known hypersensitivity to IFNB-1b or other human proteins including albumin
• Known allergy to Gadolinium-DTPA documented prior to study entry
• Known general hypersensitivity to all analgesic / antiinflammatory agents (NSAIDs)
• Participation in any MS clinical study within the past six months
• Pre-treatment with any of the following substances prior to study enrollment within said time period:
• At any time: any IFN, glatiramer acetate (Copaxone), total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (i.e. anti-CD4, anti-CD52 (alemtuzumab), anti-VLA4 (natalizumab), mitoxantrone, cyclophosphamide, azathioprine, IVIG, cyclosporine A, methotrexate, or any other immunomodulating or immunosuppressive agent including other recombinant or non-recombinant cytokines
• 3 months prior to study entry: any other treatment known to be used for putative or experimental MS treatment. Any presumed immunomodulating agent (e.g. statins) not described in this protocol
• History of alcohol or substance abuse (within the past 5 years)
• Inability or unwillingness to administer subcutaneous injections either by self or by caregiver
• Clinically significant hepatic, renal, or bone marrow dysfunction as defined by any of the following laboratory evaluations:
• Hepatic dysfunction: AST (SGOT) > 3x the upper limit of normal or total bilirubin > 2x upper limit of normal
• Renal dysfunction: creatinine > 1.8 mg/dl
• Bone marrow dysfunction: Hb < 8.5 g/dl, WBC < 2.5x10\^9/L, or platelet count < 125x10\^9/L
• Patients participating in the exploratory substudy should be excluded if they meet any of the following:
• Known history of chronic glaucoma, ocular hypertension, ischemic optic neuropathy, temporal arteritis, pseudopapilledema, retinitis pigmentosa, traumatic optic neuropathy, toxic optic neuropathy, pernicious anemia, or Leber's hereditary optic neuritis

Where it is running

• Study site — Many Locations, Alabama, United States
• Study site — Many Locations, Arizona, United States
• Study site — Many Locations, Delaware, United States
• Study site — Many Locations, District of Columbia, United States
• Study site — Many Locations, Florida, United States
• Study site — Many Locations, Georgia, United States
• Study site — Many Locations, Illinois, United States
• Study site — Many Locations, Iowa, United States
• Study site — Many Locations, Louisiana, United States
• Study site — Many Locations, Maine, United States
• Study site — Many Locations, Minnesota, United States
• Study site — Many Locations, Missouri, United States
• Study site — Many Locations, New Jersey, United States
• Study site — Many Locations, New York, United States
• Study site — Many Locations, North Carolina, United States
• Study site — Many Locations, Ohio, United States
• Study site — Many Locations, Pennsylvania, United States
• Study site — Many Locations, Tennessee, United States
• Study site — Many Locations, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.